Compare Applied Digital Corporation (APLD) vs Moderna, Inc. (MRNA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Applied Digital Corporation vs Moderna, Inc. — how do they compare? Applied Digital Corporation trades at $30.79 (market cap $8.90B), while Moderna, Inc. trades at $68.05 (market cap $27.09B). The key difference: Moderna, Inc. is far larger — about 3× Applied Digital Corporation's market cap, and Moderna, Inc. is trading nearer its 52-week high, Applied Digital Corporation nearer its low. Which is the better fit depends on your goals.
| APLD | MRNA | |
|---|---|---|
Market Cap | $8.90B | $27.09B |
Sector | Technology | Health |
52-Week High | $49.65 | $81.80 |
52-Week Low | $9.18 | $22.36 |
Enterprise Value | $10.00B | $23.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Applied Digital (APLD) trades at $31.15, down 3.53% today, amid bearish technical signals despite unanimous analyst buy ratings. The company shows strong revenue growth with $144M in 2025 and $319M projected for 2026, but remains unprofitable with negative margins. Recent news highlights APLD's pivot to AI data centers with $36B in contracted lease value, though execution risks and customer concentration persist.
Outlook: High growth potential from AI infrastructure expansion contrasts with profitability challenges and heavy capital spending. Risks include customer concentration and debt load, but analyst consensus targets $76.67 suggest significant upside if execution improves.
Moderna (MRNA) trades at $68.27, down 10.83% amid a biotech sell-off, but maintains a bullish technical trend with strong moving averages. Revenue has declined from pandemic peaks to $1.92B in 2025, with net losses widening to -$2.82B, yet recent quarterly EPS beats and pipeline expansions into oncology and flu vaccines fuel optimism. The stock remains volatile, with a consensus price target of $49.00 below the current price, reflecting mixed analyst sentiment.
The outlook hinges on pipeline execution, with EU RSV vaccine contracts and FDA decisions offering upside, but high cash burn and competitive pressures pose risks. Investors face a trade-off between growth potential and profitability challenges, with the stock's 70% monthly surge testing sustainability near-term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Applied Digital Corporation
Applied Digital provides high-performance computing (HPC) infrastructure and cloud services. It designs and operates data centers tailored for AI, machine learning, and other intensive digital workloads across North America.
Read more on APLD →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
